Ardea Biosciences, Inc. - Strategic SWOT Analysis Review

Ardea Biosciences, Inc. - Strategic SWOT Analysis Review

  • February 2015
  • 20 pages
  • GlobalData
Report ID: 344348
Ardea Biosciences, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.

Highlights

Ardea Biosciences, Inc. (Ardea) is a biotechnology company. It focuses on the development of small molecules as novel therapeutics for the treatment of gout and cancer. The company’s product portfolio includes three pipeline products, namely, Lesinurad, RDEA 3170 and Bay 86-9766. Lesinurad and RDEA 3170 are currently in Phase-III and Phase-II clinical trials respectively, being developed as a treatment for gout. Bay 86-966 is a Phase-II clinical candidate being developed as a treatment for cancer in a global licensing agreement with Bayer. The company operates as a subsidiary of AstraZeneca PLC. Ardea is headquartered in San Diego, California, the US.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Ardea Biosciences, Inc. - Key Facts 5
Ardea Biosciences, Inc. - Key Employees 6
Ardea Biosciences, Inc. - Major Products and Services 7
Ardea Biosciences, Inc. - History 8
Ardea Biosciences, Inc. - Locations And Subsidiaries 10
Head Office 10
Other Locations & Subsidiaries 10
Section 2 - Company Analysis 11
Ardea Biosciences, Inc. - Business Description 11
Ardea Biosciences, Inc. - SWOT Analysis 12
SWOT Analysis - Overview 12
Ardea Biosciences, Inc. - Strengths 12
Strength - Focused Research and Development 12
Strength - Synergy through AstraZeneca PLC 12
Strength - Global Agreement with Bayer HealthCare 12
Ardea Biosciences, Inc. - Weaknesses 13
Weakness - Lack of Commercial Products 13
Weakness - Dependence on Third Party Contractors 13
Ardea Biosciences, Inc. - Opportunities 14
Opportunity - Market Potential: Cancer Treatment 14
Opportunity - Targeting the Treatments for Gout 14
Opportunity - Changing Demographics 14
Ardea Biosciences, Inc. - Threats 15
Threat - Competitive Pressures 15
Threat - Uncertain R&D Outcomes 15
Threat - Regulatory Environment 15
Ardea Biosciences, Inc. - Key Competitors 16
Section 3 - Company's Lifesciences Financial Deals and Alliances 17
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 17
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 18
Ardea Biosciences, Inc., Recent Deals Summary 19
Section 4 - Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables

Ardea Biosciences, Inc., Key Facts 5
Ardea Biosciences, Inc., Key Employees 6
Ardea Biosciences, Inc., Major Products and Services 7
Ardea Biosciences, Inc., History 8
Ardea Biosciences, Inc., Subsidiaries 10
Ardea Biosciences, Inc., Key Competitors 16
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 17
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 18
Ardea Biosciences, Inc., Recent Deals Summary 19

List of Figures

Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 17
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 18
Country=UnitedStates Date=201502 Topic=SWOTAnalysis Publisher=GlobalData Price=1000